[14C]-rencofilstat 225mg
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NASH With Fibrosis
Conditions
NASH With Fibrosis
Trial Timeline
Mar 1, 2023 → Aug 4, 2023
NCT ID
NCT05737433About [14C]-rencofilstat 225mg
[14C]-rencofilstat 225mg is a phase 1 stage product being developed by Hepion Pharmaceuticals for NASH With Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05737433. Target conditions include NASH With Fibrosis.
What happened to similar drugs?
0 of 5 similar drugs in NASH With Fibrosis were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05737433 | Phase 1 | Completed |
Competing Products
20 competing products in NASH With Fibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 32 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 32 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 32 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 26 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 29 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 29 |
| IVA337 + Placebo | Inventiva | Phase 3 | 41 |
| AZD2693 | AstraZeneca | Phase 1 | 29 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 29 |
| LIK066 + Placebo | Novartis | Phase 2 | 35 |
| Tropifexor (LJN452) + Cenicriviroc (CVC) | Novartis | Phase 2 | 35 |
| Tropifexor + Licogliflozin | Novartis | Phase 2 | 27 |
| LMB763 + Placebo | Novartis | Phase 2 | 27 |
| Tropifexor (LJN452) + Placebo | Novartis | Phase 2 | 27 |
| TRO19622 + Placebo | Roche | Phase 2 | 35 |
| SEL + SIM | Gilead Sciences | Phase 2 | 35 |
| Seladelpar + Placebos | Gilead Sciences | Phase 2 | 27 |
| Placebo + SIM | Gilead Sciences | Phase 2 | 27 |
| Cilofexor | Gilead Sciences | Phase 1 | 29 |
| Firsocostat + Fenofibrate | Gilead Sciences | Phase 1 | 29 |